FR21C1018I2 - Dispersion solide de la forme amorphe de (r)-1(2,2-difluorobenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropane-2-yl)-1h-indol-5-yl)-cyclopropanecarboxamide - Google Patents

Dispersion solide de la forme amorphe de (r)-1(2,2-difluorobenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropane-2-yl)-1h-indol-5-yl)-cyclopropanecarboxamide

Info

Publication number: FR21C1018I2
Authority: FR; France
Prior art keywords: difluorobenzo; cyclopropanecarboxamide; dioxol; dihydroxypropyl; methylpropane
Prior art date: 2010-03-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR21C1018C

Other languages

English (en)

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Vertex Pharmaceuticals Inc

Original Assignee

Vertex Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-25

Filing date

2021-05-14

Publication date

2023-02-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43903962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR21C1018(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2021-05-14 Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc

2021-07-02 Publication of FR21C1018I1 publication Critical patent/FR21C1018I1/fr

2023-02-17 Application granted granted Critical

2023-02-17 Publication of FR21C1018I2 publication Critical patent/FR21C1018I2/fr

Status Active legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Psychology (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Emergency Medicine (AREA)
Otolaryngology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Pregnancy & Childbirth (AREA)

FR21C1018C 2010-03-25 2021-05-14 Dispersion solide de la forme amorphe de (r)-1(2,2-difluorobenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropane-2-yl)-1h-indol-5-yl)-cyclopropanecarboxamide Active FR21C1018I2 (fr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US31737610P	2010-03-25	2010-03-25
US31995310P	2010-04-01	2010-04-01
US32156110P	2010-04-07	2010-04-07
US32163610P	2010-04-07	2010-04-07
PCT/US2011/030032 WO2011119984A1 (fr)	2010-03-25	2011-03-25	Formes solides de (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide
EP11713134.2A EP2563778B1 (fr)	2010-03-25	2011-03-25	Forme cristalline de (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide

Publications (2)

Publication Number	Publication Date
FR21C1018I1 FR21C1018I1 (fr)	2021-07-02
FR21C1018I2 true FR21C1018I2 (fr)	2023-02-17

Family

ID=43903962

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR21C1018C Active FR21C1018I2 (fr)	2010-03-25	2021-05-14	Dispersion solide de la forme amorphe de (r)-1(2,2-difluorobenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropane-2-yl)-1h-indol-5-yl)-cyclopropanecarboxamide

Country Status (26)

Country	Link
US (1)	US20110251253A1 (fr)
EP (5)	EP3181561B1 (fr)
JP (5)	JP5734410B2 (fr)
CN (3)	CN106083832A (fr)
AU (3)	AU2011230508B2 (fr)
BR (1)	BR112012024338B1 (fr)
CA (2)	CA2794559C (fr)
CY (3)	CY1123794T1 (fr)
DK (1)	DK2826776T3 (fr)
ES (4)	ES2845449T3 (fr)
FR (1)	FR21C1018I2 (fr)
HR (2)	HRP20230661T1 (fr)
HU (3)	HUE062892T2 (fr)
IL (4)	IL222117B (fr)
LT (2)	LT2826776T (fr)
LU (1)	LUC00207I2 (fr)
MX (3)	MX345541B (fr)
NO (1)	NO2021021I1 (fr)
NZ (3)	NZ718018A (fr)
PL (2)	PL3835297T3 (fr)
PT (1)	PT2826776T (fr)
RS (1)	RS61314B1 (fr)
RU (1)	RU2711481C2 (fr)
SI (1)	SI2826776T1 (fr)
SM (1)	SMT202100051T1 (fr)
WO (1)	WO2011119984A1 (fr)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2006111093A (ru)	2003-09-06	2007-10-27	Вертекс Фармасьютикалз Инкорпорейтед (Us)	Модуляторы атр-связывающих кассетных транспортеров
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
RS56037B1 (sr)	2004-06-24	2017-09-29	Vertex Pharma	Modulatori atp-vezujućih kasetnih transportera
US7999113B2 (en)	2005-08-11	2011-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CN102775396B (zh)	2005-11-08	2014-10-08	沃泰克斯药物股份有限公司	Atp-结合弹夹转运蛋白的杂环调控剂
EP3219705B1 (fr)	2005-12-28	2020-03-11	Vertex Pharmaceuticals Incorporated	Compositions pharmaceutiques de la forme amorphe de n- [2,4-bis (1,1-diméthyléthyl) -5-hydroxyphényl] -1,4-dihydro-4-oxoquinoline-3-carboxamide
CA2856037C (fr)	2005-12-28	2017-03-07	Vertex Pharmaceuticals Incorporated	Modulateurs de transporteurs a cassette liant l'atp
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
EP2674428B1 (fr)	2006-04-07	2016-04-06	Vertex Pharmaceuticals Incorporated	Modulateurs des transporteurs de cassettes de liaison de l'ATP
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
CN104447716A (zh)	2007-05-09	2015-03-25	沃泰克斯药物股份有限公司	Cftr调节剂
JP5389030B2 (ja)	2007-08-24	2014-01-15	バーテックスファーマシューティカルズインコーポレイテッド	（特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン
SI2578571T1 (sl)	2007-11-16	2016-01-29	Vertex Pharmaceuticals Incorporated	Izokinolinski modulatorji prenašalcev z atp-vezavno kaseto
MX365732B (es)	2007-12-07	2019-06-12	Vertex Pharma	Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
EP3683218B1 (fr)	2007-12-07	2024-09-18	Vertex Pharmaceuticals Incorporated	Formes solides d'acide benzoïque 3-(6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl)
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
NZ720282A (en)	2008-02-28	2017-12-22	Vertex Pharma	Heteroaryl derivatives as cftr modulators
NZ616097A (en)	2008-03-31	2015-04-24	Vertex Pharma	Pyridyl derivatives as cftr modulators
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
AR073709A1 (es)	2008-09-29	2010-11-24	Vertex Pharma	Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico
PL2408750T3 (pl)	2009-03-20	2016-02-29	Vertex Pharma	Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX2012011655A (es)	2010-04-07	2012-11-23	Vertex Pharma	Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico.
JP2013523833A (ja)	2010-04-07	2013-06-17	バーテックスファーマシューティカルズインコーポレイテッド	３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
MX353408B (es) *	2010-04-22	2018-01-11	Vertex Pharma	Proceso para producir compuestos de cicloalquilcarboxamido-indol.
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
WO2013070961A1 (fr)	2011-11-08	2013-05-16	Vertex Pharmaceuticals Incorporated	Modulateurs de transporteurs de cassette de liaison à l'atp
US20130172375A1 (en) *	2011-12-13	2013-07-04	Hoffmann-La Roche Inc.	Pharmaceutical composition
NZ727015A (en)	2012-01-25	2017-12-22	Vertex Pharma	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
JP2015511583A (ja)	2012-02-27	2015-04-20	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	薬学的組成物およびその投与
US8674108B2 (en)	2012-04-20	2014-03-18	Vertex Pharmaceuticals Incorporated	Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AR092857A1 (es)	2012-07-16	2015-05-06	Vertex Pharma	Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
MX365950B (es)	2013-03-13	2019-06-19	Flatley Discovery Lab Llc	Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
CN104415345A (zh) *	2013-08-30	2015-03-18	天津药物研究院	一种多元复合物及其制备方法
AU2014349010C1 (en)	2013-11-12	2020-08-06	Vertex Pharmaceuticals Incorporated	Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
RU2744460C2 (ru) *	2014-04-15	2021-03-09	Вертекс Фармасьютикалз Инкорпорейтед	Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости
MA41051B1 (fr)	2014-10-06	2020-11-30	Vertex Pharma	Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
CN107250113B (zh)	2014-10-07	2019-03-29	弗特克斯药品有限公司	囊性纤维化跨膜传导调节蛋白的调节剂的共晶
DK3212189T3 (da) *	2014-10-31	2020-10-26	Abbvie Overseas Sarl	Substituerede chromaner og fremgangsmåde til anvendelse deraf
RU2691136C2 (ru)	2014-11-18	2019-06-11	Вертекс Фармасьютикалз Инкорпорейтед	Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
EP3240539A4 (fr)	2014-12-31	2018-07-25	Auspex Pharmaceuticals, Inc.	Cyclopropanecarboxamides comme modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
EP3277647A1 (fr)	2015-03-31	2018-02-07	Vertex Pharmaceuticals (Europe) Limited	Vx-661 deutéré
CN105130949B (zh) *	2015-09-02	2019-01-29	阜新奥瑞凯新材料有限公司	1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙基腈的制备方法
WO2017180794A1 (fr)	2016-04-13	2017-10-19	Skyline Antiinfectives, Inc.	Acides hydroxamiques de bêta-lactame o-sulfatés deutérés et bêta-lactames n-sulfatés deutérés
US10206915B2 (en)	2016-04-25	2019-02-19	Druggability Technologies Ip Holdco Limited	Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10383865B2 (en)	2016-04-25	2019-08-20	Druggability Technologies Ip Holdco Limited	Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
HUP1600270A2 (hu)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Ivacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadott készítményei
HUP1600271A2 (hu)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei
CN109803962B (zh)	2016-09-30	2022-04-29	弗特克斯药品有限公司	囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物
US10399940B2 (en) *	2016-10-07	2019-09-03	Abbvie S.Á.R.L.	Substituted pyrrolidines and methods of use
MD3551622T2 (ro)	2016-12-09	2021-03-31	Vertex Pharma	Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului
US11253509B2 (en)	2017-06-08	2022-02-22	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
US20210069174A1 (en)	2017-07-01	2021-03-11	Vertex Pharmaceuticals Incorporated	Compositions and methods for treatment of cystic fibrosis
US20200171015A1 (en)	2017-07-17	2020-06-04	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
MA49631A (fr)	2017-07-17	2020-05-27	Vertex Pharma	Méthodes de traitement de la fibrose kystique
JP7121794B2 (ja)	2017-08-02	2022-08-18	バーテックスファーマシューティカルズインコーポレイテッド	ピロリジン化合物を調製するためのプロセス
WO2019079760A1 (fr)	2017-10-19	2019-04-25	Vertex Pharmaceuticals Incorporated	Formes cristallines et compositions de modulateurs de cftr
CN107880011B (zh) *	2017-11-27	2019-08-16	山东省医学科学院药物研究所	鲁玛卡托关键中间体的合成方法
WO2019113089A1 (fr)	2017-12-04	2019-06-13	Vertex Pharmaceuticals Incorporated	Compositions pour le traitement de la mucoviscidose
EP3720849A2 (fr)	2017-12-08	2020-10-14	Vertex Pharmaceuticals Incorporated	Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose
TWI810243B (zh)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	用於治療囊腫纖化症之醫藥組合物
JP7214743B2 (ja)	2018-02-15	2023-01-30	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法
CN110193012B (zh) *	2018-02-27	2022-02-08	江苏恒瑞医药股份有限公司	一种氧代吡啶酰胺类衍生物的药物组合物及其制备方法
WO2019195739A1 (fr)	2018-04-05	2019-10-10	Alexander Russell Abela	Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
EP3774825A1 (fr)	2018-04-13	2021-02-17	Vertex Pharmaceuticals Incorporated	Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
EA202191361A1 (ru)	2018-11-14	2021-08-11	Вертекс Фармасьютикалз Инкорпорейтед	Способы лечения муковисцидоза
CA3067611A1 (fr)	2019-01-15	2020-07-15	Apotex Inc.	Procede de preparation de tezacaftor et intermediaires connexes
UY38630A (es)	2019-04-03	2020-10-30	Vertex Pharma	Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
WO2020214921A1 (fr)	2019-04-17	2020-10-22	Vertex Pharmaceuticals Incorporated	Formes solides de modulateurs de cftr
UY38696A (es)	2019-05-14	2020-11-30	Vertex Pharma	Moduladores de alfa-1 antitripsina
WO2020242935A1 (fr)	2019-05-29	2020-12-03	Vertex Pharmaceuticals Incorporated	Méthodes de traitement de la mucoviscidose
WO2021030552A1 (fr)	2019-08-14	2021-02-18	Vertex Pharmaceuticals Incorporated	Formes cristallines de modulateurs de cftr
US20220313698A1 (en)	2019-08-14	2022-10-06	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
TWI867024B (zh)	2019-08-14	2024-12-21	美商維泰克斯製藥公司	囊腫纖維化跨膜傳導調節蛋白之調節劑
TWI899097B (zh)	2019-08-14	2025-10-01	美商維泰克斯製藥公司	製備cftr調節劑之方法
WO2021140525A1 (fr) *	2020-01-07	2021-07-15	Msn Laboratories Private Limited, R&D Center	Nouvelle forme cristalline de 1-(2,2-difluoro-2h-1,3-benzodioxol-5-yl)-n-{1-[(2r)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-méthylpropan-2-yl)-1h-indol-5-yl}cyclopropane-1-carboxamide et son procédé de préparation
WO2021176064A1 (fr)	2020-03-06	2021-09-10	Química Sintética, S.A.	Formes solides de tezacaftor et leurs procédés de préparation
WO2022194399A1 (fr)	2020-07-13	2022-09-22	Idorsia Pharmaceuticals Ltd	Macrocycles en tant que modulateurs de cftr
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
IL300413A (en)	2020-08-13	2023-04-01	Vertex Pharma	Crystal forms of CFTR modulators
WO2022076626A1 (fr)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulateurs du régulateur de conductance transmembranaire de la fibrose kystique
US20230373935A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230373974A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225737A1 (fr)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
AU2021356651A1 (en)	2020-10-07	2023-05-18	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225761A1 (fr)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
KR20230104618A (ko)	2020-10-07	2023-07-10	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막관통 전도도 조절자의 조절제
EP4225446A1 (fr)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
WO2022076622A2 (fr)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
EP4225762A1 (fr)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
WO2022109553A2 (fr)	2020-11-17	2022-05-27	Vertex Pharmaceuticals Incorporated	Formes solides de l'acide 4-(5-(4-fluorophényl)-6-tétrahydro-2h-pyran-4-yl)-1,5-dihydropyrrolo[2,3-f]indazol-7-yl)benzoïque
US12324802B2 (en)	2020-11-18	2025-06-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
KR20230118123A (ko)	2020-12-10	2023-08-10	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 치료 방법
CA3249865A1 (fr)	2022-02-03	2023-08-10	Vertex Pharmaceuticals Incorporated	Procédés de préparation et formes cristallines de (6a,12a)-17-amino-12-méthyl-6,15-bis(trifluorométhyl)-13,19-dioxa-3,4,18-triazatricyclo[12.3.1.12,5]nonadéca-1(18),2,4,14,16-pentaén-6-ol
JP2025506382A (ja)	2022-02-03	2025-03-11	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症の治療方法
JP2025505643A (ja)	2022-02-08	2025-02-28	バーテックスファーマシューティカルズインコーポレイテッド	嚢胞性線維症膜コンダクタンス制御因子の調節因子
CA3258118A1 (fr)	2022-04-06	2023-10-12	Vertex Pharmaceuticals Incorporated	Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
JP2025517323A (ja)	2022-05-16	2025-06-05	バーテックスファーマシューティカルズインコーポレイテッド	Ｃｆｔｒモジュレーターとしての大環状化合物の固体形態及びその調製
WO2023224931A1 (fr)	2022-05-16	2023-11-23	Vertex Pharmaceuticals Incorporated	Méthodes de traitement de la fibrose kystique
US20260034064A1 (en)	2022-08-04	2026-02-05	Vertex Pharmaceuticals Incorporated	Compositions for the treatment of cftr-mediated diseases
WO2024056798A1 (fr)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Modulateurs du cftr macrocycliques
CN119998297A (zh)	2022-09-15	2025-05-13	爱杜西亚药品有限公司	(3S,7S,10R,13R)-13-苄基-20-氟-7-异丁基-N-(2-(3-甲氧基-1,2,4-噁二唑-5-基)乙基)-6,9-二甲基-1,5,8,11-四氧代-10-(2,2,2-三氟乙基)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-十四氢-[1]氧杂[4,7,10,14]四氮杂环十七烷并[16,17-f]喹啉-3-甲酰胺的晶型
CA3267788A1 (fr)	2022-09-15	2024-03-21	Idorsia Pharmaceuticals Ltd	Association de modulateurs de cftr macrocycliques avec des correcteurs de cftr et/ou des potentialisateurs de cftr
WO2025076235A1 (fr)	2023-10-04	2025-04-10	Vertex Pharmaceuticals Incorporated	Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique
WO2025076240A1 (fr)	2023-10-04	2025-04-10	Vertex Pharmaceuticals Incorporated	Formes solides de modulateurs du régulateur de la perméabilité transmembranaire de la fibrose kystique
WO2025166342A1 (fr)	2024-02-04	2025-08-07	Vertex Pharmaceuticals Incorporated	Combinaison de vanzacaftor, de tezacaftor et de deutivacaftor destinée à être utilisée dans le traitement de la fibrose kystique
EP4648753B1 (fr)	2024-02-07	2026-02-18	Vertex Pharmaceuticals Incorporated	Compositions pour le traitement de maladies médiées par cftr
WO2025186214A1 (fr)	2024-03-05	2025-09-12	Idorsia Pharmaceuticals Ltd	Modulateurs de cftr macrocycliques
WO2026006653A1 (fr)	2024-06-28	2026-01-02	Vertex Pharmaceuticals Incorporated	Combinaison comprenant elexacaftor/tezacaftor/ivacaftor destiné à être utilisée dans le traitement de la fibrose kystique où le patient présente au moins une mutation cftr

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5886026A (en)	1993-07-19	1999-03-23	Angiotech Pharmaceuticals Inc.	Anti-angiogenic compositions and methods of use
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
ATE364374T1 (de) *	1997-08-11	2007-07-15	Pfizer Prod Inc	Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US20020017295A1 (en)	2000-07-07	2002-02-14	Weers Jeffry G.	Phospholipid-based powders for inhalation
HUP0301493A2 (hu) *	2000-03-09	2003-08-28	Ono Pharmaceutical Co., Ltd.	Indolszármazékok, eljárás előállításukra és alkalmazásuk
US6777400B2 (en)	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
US20060083784A1 (en) *	2002-08-07	2006-04-20	Smithkline Beecham Corporation	Amorphous pharmaceutical compositions
BR0314943A (pt)	2002-09-30	2005-08-02	Univ California	Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes
JP2004131393A (ja) *	2002-10-08	2004-04-30	Kowa Co	易溶出性製剤
US20050113423A1 (en)	2003-03-12	2005-05-26	Vangoor Frederick F.	Modulators of ATP-binding cassette transporters
EP4101846B1 (fr)	2003-04-11	2023-08-02	PTC Therapeutics, Inc.	Composés d'acide benzoïque 1,2,4-oxadiazole et leur utilisation pour la suppression non-sens et le traitement de maladies
US7696244B2 (en)	2003-05-16	2010-04-13	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
DE602004022819D1 (de)	2003-06-06	2009-10-08	Vertex Pharma	Von atp-bindende kassette transportern
EP1680411A2 (fr)	2003-10-08	2006-07-19	Vertex Pharmaceuticals Incorporated	Modulateurs des transporteurs des cassettes de fixation de l'atp contenant des groupes cycloalkyle ou pyranyle
CN101675928A (zh)	2003-11-14	2010-03-24	沃泰克斯药物股份有限公司	可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑
EP1740532A4 (fr)	2004-03-30	2009-06-10	Univ California	Composes inhibiteurs de cftr contenant des hydrazides et utilisations de ceux-ci
CA2569402A1 (fr)	2004-06-04	2005-12-22	The Regents Of The University Of California	Composes intervenant dans l'acceleration du transport ionique par le cftr mutant, et utilisations desdits composes
EP1799659A1 (fr)	2004-10-13	2007-06-27	PTC Therapeutics, Inc.	Composés permettant de supprimer les effets des mutations non-sens, et méthodes d emploi desdits composés
JP5385605B2 (ja)	2005-03-11	2014-01-08	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｐ結合カセットトランスポーターのモジュレーター
CA2600869A1 (fr)	2005-03-18	2006-09-28	The Regents Of The University Of California	Composes possedant une activite de correction du traitement de mutant-cftr et utilisations de ceux-ci
PL2402002T3 (pl)	2005-04-08	2018-11-30	Ptc Therapeutics, Inc.	Kompozycje zawierające kwas 1,2,4-oksadiazolobenzoesowy i ich zastosowania do leczenia chorób związanych z przedwczesnym kodonem stop
JP5426878B2 (ja)	2005-05-24	2014-02-26	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｐ−結合カセットトランスポーターのモジュレーター
ES2367844T3 (es) *	2005-08-11	2011-11-10	Vertex Pharmaceuticals, Inc.	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística.
EP1926476B1 (fr) *	2005-08-29	2013-04-10	Sanofi-Aventis U.S. LLC	Dispersions solides amorphes de 7-chloro-n,n-5-triméthyl-4-oxo- 3.phényl-3,5-di hydro-4h-pyridazino[4,5 -b]indole-1-acétamide
KR20080064971A (ko)	2005-10-06	2008-07-10	버텍스 파마슈티칼스 인코포레이티드	Ａｔｐ-결합 카세트 전달체의 조절자
US20070218138A1 (en) *	2006-03-20	2007-09-20	Bittorf Kevin J	Pharmaceutical Compositions
TWI428125B (zh) *	2006-03-20	2014-03-01	Vertex Pharma	對包括vx-950之藥物實施噴霧乾燥之方法及由此方法製備之產物
US7645789B2 (en) *	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
EP2674428B1 (fr) *	2006-04-07	2016-04-06	Vertex Pharmaceuticals Incorporated	Modulateurs des transporteurs de cassettes de liaison de l'ATP
WO2008064259A2 (fr) *	2006-11-21	2008-05-29	Biokey, Inc.	Composition de dispersion solide
TWI482768B (zh) *	2007-11-22	2015-05-01	Zenyaku Kogyo Kk	雜環化合物之非晶質體、含有其之固體分散體、藥劑及其製法
EP3683218B1 (fr) *	2007-12-07	2024-09-18	Vertex Pharmaceuticals Incorporated	Formes solides d'acide benzoïque 3-(6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl)
EP2940016A1 (fr) *	2008-11-06	2015-11-04	Vertex Pharmaceuticals Incorporated	Modulateurs de transporteurs de cassette à liaison ATP
UA104876C2 (uk) *	2008-11-06	2014-03-25	Вертекс Фармасьютікалз Інкорпорейтед	Модулятори atф-зв'язувальних касетних транспортерів
MX2012004792A (es) *	2009-10-22	2013-02-01	Vertex Pharma	Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
MX353408B (es) *	2010-04-22	2018-01-11	Vertex Pharma	Proceso para producir compuestos de cicloalquilcarboxamido-indol.
CA2796602A1 (fr) *	2010-04-22	2011-10-27	Vertex Pharmaceuticals Incorporated	Compositions pharmaceutiques et leurs administrations
WO2012027247A2 (fr) *	2010-08-23	2012-03-01	Vertex Pharmaceuticals Incorporated	Composition pharmaceutique à base de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropan-2-yl)-1h-indol-5-yle)cyclopropane carboxamide et son administration

2011
- 2011-03-25 SI SI201131935T patent/SI2826776T1/sl unknown
- 2011-03-25 JP JP2013501522A patent/JP5734410B2/ja active Active
- 2011-03-25 PL PL20206423.4T patent/PL3835297T3/pl unknown
- 2011-03-25 NZ NZ718018A patent/NZ718018A/en unknown
- 2011-03-25 HR HRP20230661TT patent/HRP20230661T1/hr unknown
- 2011-03-25 RU RU2015153068A patent/RU2711481C2/ru active
- 2011-03-25 MX MX2016001939A patent/MX345541B/es unknown
- 2011-03-25 DK DK14172991.3T patent/DK2826776T3/da active
- 2011-03-25 CN CN201610452877.3A patent/CN106083832A/zh active Pending
- 2011-03-25 ES ES14172991T patent/ES2845449T3/es active Active
- 2011-03-25 EP EP17154840.7A patent/EP3181561B1/fr active Active
- 2011-03-25 CA CA2794559A patent/CA2794559C/fr active Active
- 2011-03-25 BR BR112012024338-1A patent/BR112012024338B1/pt active IP Right Grant
- 2011-03-25 CA CA3016080A patent/CA3016080C/fr active Active
- 2011-03-25 EP EP14172991.3A patent/EP2826776B1/fr active Active
- 2011-03-25 HU HUE20206423A patent/HUE062892T2/hu unknown
- 2011-03-25 CN CN201180025743.9A patent/CN102892764B/zh active Active
- 2011-03-25 PL PL14172991T patent/PL2826776T3/pl unknown
- 2011-03-25 NZ NZ700556A patent/NZ700556A/en unknown
- 2011-03-25 PT PT141729913T patent/PT2826776T/pt unknown
- 2011-03-25 ES ES11713134.2T patent/ES2604105T3/es active Active
- 2011-03-25 EP EP20206423.4A patent/EP3835297B1/fr active Active
- 2011-03-25 EP EP23166117.4A patent/EP4253381A3/fr active Pending
- 2011-03-25 ES ES17154840T patent/ES2804202T3/es active Active
- 2011-03-25 ES ES20206423T patent/ES2951520T3/es active Active
- 2011-03-25 US US13/072,380 patent/US20110251253A1/en not_active Abandoned
- 2011-03-25 HU HUE14172991A patent/HUE052759T2/hu unknown
- 2011-03-25 AU AU2011230508A patent/AU2011230508B2/en active Active
- 2011-03-25 WO PCT/US2011/030032 patent/WO2011119984A1/fr not_active Ceased
- 2011-03-25 SM SM20210051T patent/SMT202100051T1/it unknown
- 2011-03-25 LT LTEP14172991.3T patent/LT2826776T/lt unknown
- 2011-03-25 EP EP11713134.2A patent/EP2563778B1/fr active Active
- 2011-03-25 CN CN201810927753.5A patent/CN109081804B/zh active Active
- 2011-03-25 MX MX2017001548A patent/MX370904B/es unknown
- 2011-03-25 RS RS20210007A patent/RS61314B1/sr unknown
- 2011-03-25 MX MX2012011062A patent/MX347804B/es active IP Right Grant
- 2011-03-25 NZ NZ602665A patent/NZ602665A/en unknown
2012
- 2012-09-24 IL IL222117A patent/IL222117B/en active IP Right Grant
2015
- 2015-03-09 JP JP2015046120A patent/JP2015127334A/ja active Pending
2016
- 2016-07-27 AU AU2016208341A patent/AU2016208341B2/en active Active
- 2016-10-20 JP JP2016206062A patent/JP6326570B2/ja active Active
2017
- 2017-12-21 JP JP2017245323A patent/JP6913623B2/ja active Active
2018
- 2018-02-15 IL IL257542A patent/IL257542B/en active IP Right Grant
- 2018-05-07 AU AU2018203149A patent/AU2018203149B2/en active Active
2019
- 2019-10-18 IL IL270047A patent/IL270047B/en unknown
2020
- 2020-03-18 JP JP2020047688A patent/JP6964702B2/ja active Active
2021
- 2021-02-01 HR HRP20210165TT patent/HRP20210165T1/hr unknown
- 2021-02-08 CY CY20211100108T patent/CY1123794T1/el unknown
- 2021-05-14 LT LTPA2021508C patent/LTC2826776I2/lt unknown
- 2021-05-14 FR FR21C1018C patent/FR21C1018I2/fr active Active
- 2021-05-17 HU HUS2100019C patent/HUS2100019I1/hu unknown
- 2021-05-18 LU LU00207C patent/LUC00207I2/en unknown
- 2021-05-19 CY CY2021014C patent/CY2021014I1/el unknown
- 2021-05-21 NO NO2021021C patent/NO2021021I1/no unknown
- 2021-11-25 IL IL288388A patent/IL288388A/en unknown
2023
- 2023-08-03 CY CY20231100390T patent/CY1126143T1/el unknown

Also Published As

Publication number	Publication date
PT2826776T (pt)	2021-02-01
CA3016080C (fr)	2019-08-20
EP2826776A1 (fr)	2015-01-21
WO2011119984A1 (fr)	2011-09-29
JP2018048207A (ja)	2018-03-29
JP2020094068A (ja)	2020-06-18
EP4253381A2 (fr)	2023-10-04
MX370904B (es)	2020-01-09
RU2015153068A (ru)	2019-01-17
CN109081804A (zh)	2018-12-25
CA2794559A1 (fr)	2011-09-29
EP2563778B1 (fr)	2016-08-24
CN109081804B (zh)	2021-12-10
LTPA2021508I1 (fr)	2021-06-10
MX2012011062A (es)	2013-01-14
CY1126143T1 (el)	2023-11-15
CY1123794T1 (el)	2021-09-14
SI2826776T1 (sl)	2021-02-26
JP6913623B2 (ja)	2021-08-04
ES2604105T3 (es)	2017-03-03
ES2804202T3 (es)	2021-02-04
FR21C1018I1 (fr)	2021-07-02
EP2563778A1 (fr)	2013-03-06
BR112012024338B1 (pt)	2021-09-28
SMT202100051T1 (it)	2021-03-15
LTC2826776I2 (fr)	2023-12-11
HUS2100019I1 (hu)	2021-06-28
NZ602665A (en)	2014-10-31
AU2011230508A1 (en)	2012-10-18
JP6964702B2 (ja)	2021-11-10
JP2017008120A (ja)	2017-01-12
IL222117B (en)	2018-02-28
DK2826776T3 (da)	2020-12-14
CY2021014I2 (el)	2021-10-15
RU2711481C2 (ru)	2020-01-17
NZ718018A (en)	2017-10-27
RU2015153068A3 (fr)	2019-07-17
RU2012145295A (ru)	2014-04-27
JP5734410B2 (ja)	2015-06-17
AU2018203149A1 (en)	2018-05-24
BR112012024338A2 (pt)	2020-09-01
RU2573830C2 (ru)	2016-01-27
ES2951520T3 (es)	2023-10-23
HRP20210165T1 (hr)	2021-03-19
JP6326570B2 (ja)	2018-05-23
ES2845449T3 (es)	2021-07-26
IL257542A (en)	2018-04-30
EP3835297B1 (fr)	2023-06-07
RS61314B1 (sr)	2021-02-26
HUE062892T2 (hu)	2023-12-28
MX347804B (es)	2017-05-15
JP2013523655A (ja)	2013-06-17
PL3835297T3 (pl)	2023-09-11
EP3181561A1 (fr)	2017-06-21
IL270047B (en)	2022-01-01
IL288388A (en)	2022-01-01
AU2018203149B2 (en)	2019-07-25
AU2016208341B2 (en)	2018-05-24
CY2021014I1 (el)	2021-10-15
CN102892764A (zh)	2013-01-23
LUC00207I2 (fr)	2024-10-04
HUE052759T2 (hu)	2021-05-28
NZ700556A (en)	2016-04-29
EP4253381A3 (fr)	2023-11-01
US20110251253A1 (en)	2011-10-13
AU2016208341A1 (en)	2016-08-18
CA2794559C (fr)	2019-07-23
CN106083832A (zh)	2016-11-09
IL257542B (en)	2020-05-31
NO2021021I1 (no)	2021-05-21
EP3835297A1 (fr)	2021-06-16
CN102892764B (zh)	2016-07-06
EP3835297C0 (fr)	2023-06-07
CA3016080A1 (fr)	2011-09-29
AU2011230508B2 (en)	2016-04-28
HRP20230661T1 (hr)	2023-09-29
MX345541B (es)	2017-02-03
EP2826776B1 (fr)	2020-11-25
EP3181561B1 (fr)	2020-05-20
LT2826776T (lt)	2021-01-11
PL2826776T3 (pl)	2021-05-31
JP2015127334A (ja)	2015-07-09

Publication	Publication Date	Title
FR21C1018I2 (fr)	2023-02-17	Dispersion solide de la forme amorphe de (r)-1(2,2-difluorobenzo(d)(1,3)dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-méthylpropane-2-yl)-1h-indol-5-yl)-cyclopropanecarboxamide
SMT201600174B (it)	2016-08-31	Forme solide di acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]diossol-5-il)ciclopropancarbossammido)-3-metilpiridin-2-il)benzoico
BRPI0911764A2 (pt)	2015-10-06	inibidores cíclicos de 11beta-hidroxiesteroide desigrogenase 1
DOP2009000202A (es)	2009-09-15	Compuesto anulares fusionados como agonistas parciales de ppar-gamma
DE502008001391D1 (de)	2010-11-04	Heteroaroylsubstituierte serin-amide
EP2248360A4 (fr)	2012-01-04	Différentiation de tonalité de vibration
EP2510089A4 (fr)	2013-06-12	Synthèse de composés prazoles
BRPI0820689A2 (pt)	2019-09-24	processo de produção de um derivado de indolinona
EP2454227A4 (fr)	2015-09-16	Synthèse de prostanoïdes
PT2260053E (pt)	2014-08-29	Análogos de oxitocina
EP2632461A4 (fr)	2014-04-02	Composés d'isoindolinone utiles comme inhibiteurs de pde 10
BR112012002336A2 (pt)	2016-05-31	compostos aza-heterocíclicos
SMT201600031B (it)	2016-02-25	Composti eterociclici di fenossimetile
EP2470074A4 (fr)	2014-11-12	Estimation de forme d'instrument
EP2178371A4 (fr)	2012-01-25	Modulateurs hétérocycliques de récepteurs cannabinoïdes
IT1392813B1 (it)	2012-03-23	Forme cristalline di dexlansoprazolo
EP2296095A4 (fr)	2011-06-01	Générateur de descripteurs vidéo
BRPI0914941A2 (pt)	2017-06-20	preparação de inibidores de incrustação ambientalmente aceitáveis
EP2383313A4 (fr)	2014-06-25	Encre de marquage
NO20090798L (no)	2010-08-20	Beskyttelsesstruktur for beskyttelse av undersjoisk utstyr
BR112013008049A2 (pt)	2016-06-21	processo de síntese de compostos beta-dicarbonilados
EP2509970A4 (fr)	2013-05-08	Dépolymérisation d'éthers cycliques oligomères
IT1394292B1 (it)	2012-06-06	Procedimento per la sintesi di pregabalina
EP2365753A4 (fr)	2012-07-04	Méthode de synthèse de désoxyribofurannoses
ES1069389Y (es)	2009-06-16	"dispositivo para representacion cromatica del sonido ambiente"